Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors

Add time:08/31/2019    Source:sciencedirect.com

We have previously reported the imidazo[1,2-a]pyridine derivative 4 as a novel p110α inhibitor; however, although 4 is a potent inhibitor of p110α enzymatic activity and tumor cell proliferation in vitro, it is unstable in solution and ineffective in vivo. To increase stability the pyrazole of 4 was replaced with a hydrazone and a moderately potent p110α inhibitor 7a was obtained. Subsequent optimization of 7a afforded exceptionally potent p110α inhibitors, including 8c and 8h, with IC50 values of 0.30 nM and 0.26 nM, respectively; to the best of our knowledge, these compounds are the most potent PI3K p110α inhibitors reported to date. Compound 8c was also stable in solution and exhibited significant anti-tumor effectiveness in vivo.

We also recommend Trading Suppliers and Manufacturers of (6-BROMOIMIDAZO[1,2-A]PYRIDIN-2-YL)METHANOL (cas 136117-71-0). Pls Click Website Link as below: cas 136117-71-0 suppliers

Prev:Research paperDesign and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells
Next:NaBH4-TMEDA and a palladium catalyst as efficient regio- and chemoselective system for the hydrodehalogenation of halogenated heterocycles)